Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2 × 2, Phase II Trial.
; Grishina, Olga
; Schmoor, Claudia
; Schlenk, Richard F
; Jost, Edgar
; Crysandt, Martina; Heuser, Michael; Thol, Felicitas; Salih, Helmut R; Schittenhelm, Marcus M; Germing, Ulrich; Kuendgen, Andrea; Götze, Katharina S; Lindemann, Hans-Walter; Müller-Tidow, Carsten; Heil, Gerhard; Scholl, Sebastian; Bug, Gesine; Schwaenen, Carsten; Giagounidis, Aristoteles; Neubauer, Andreas; Krauter, Jürgen; Brugger, Wolfram; De Wit, Maike; Wäsch, Ralph; Becker, Heiko; May, Annette M; Duyster, Justus; Döhner, Konstanze; Ganser, Arnold; Hackanson, Björn; Döhner, Hartmut; ,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Volume 38 (3): 14 – Jan 15, 2020
DNA-hypomethylating agents are studied in combination with other epigenetic drugs, such as histone deacetylase inhibitors or differentiation inducers (eg, retinoids), in myeloid neoplasias. A randomized, phase II trial with a 2 × 2 factorial design was conducted to investigate the effects of the histone deacetylase inhibitor valproate and all-trans retinoic acid (ATRA) in treatment-naive elderly patients with acute myeloid leukemia (AML).